Patrick Therasse

28.5k total citations · 5 hit papers
36 papers, 20.5k citations indexed

About

Patrick Therasse is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Patrick Therasse has authored 36 papers receiving a total of 20.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 18 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Patrick Therasse's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (11 papers) and Cancer Genomics and Diagnostics (8 papers). Patrick Therasse is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (11 papers) and Cancer Genomics and Diagnostics (8 papers). Patrick Therasse collaborates with scholars based in Belgium, Netherlands and United States. Patrick Therasse's co-authors include Elizabeth A. Eisenhauer, Jaap Verweij, Larry Rubinstein, Richard Kaplan, Allan T. van Oosterom, Susan G. Arbuck, J. Wanders, Michaele C. Christian, M. van Glabbeke and Jan Bogaerts and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Lancet Oncology.

In The Last Decade

Patrick Therasse

36 papers receiving 20.1k citations

Hit Papers

New Guidelines to Evaluate the Response to Treatment in S... 2000 2026 2008 2017 2000 2017 2016 2006 2002 4.0k 8.0k 12.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. New Guidelines to Evaluate the Response to Treatment in Solid Tumors
    2000 13.6k citations Patrick Therasse, Susan G. Arbuck et al. JNCI Journal of the National Cancer Institute profile →
  2. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
    2017 1.5k citations Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology profile →
  3. RECIST 1.1—Update and clarification: From the RECIST committee
    2016 1.2k citations Lawrence H. Schwartz, Saskia Litière et al. European Journal of Cancer profile →
  4. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
    2006 842 citations Marc Buyse, Sherene Loi et al. JNCI Journal of the National Cancer Institute profile →
  5. Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
    2002 657 citations C. Debruyne, Richard Sylvester et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Therasse Belgium 23 10.9k 8.6k 3.8k 3.6k 3.3k 36 20.5k
Margaret Mooney United States 22 12.1k 1.1× 9.8k 1.1× 3.9k 1.0× 3.2k 0.9× 4.1k 1.3× 70 23.0k
Stephen J. Gwyther United Kingdom 18 12.4k 1.1× 10.3k 1.2× 3.8k 1.0× 3.2k 0.9× 4.5k 1.4× 30 23.4k
P. Therasse Belgium 27 12.4k 1.1× 10.5k 1.2× 4.2k 1.1× 3.2k 0.9× 4.6k 1.4× 57 24.1k
E. Eisenhauer Canada 24 11.9k 1.1× 9.8k 1.1× 3.7k 1.0× 3.3k 0.9× 4.3k 1.3× 62 22.7k
J. Wanders Netherlands 38 11.1k 1.0× 7.9k 0.9× 2.8k 0.7× 4.2k 1.2× 2.3k 0.7× 132 19.6k
Lalitha Shankar United States 27 13.7k 1.3× 11.4k 1.3× 4.4k 1.2× 3.5k 1.0× 6.2k 1.9× 84 27.0k
Allan T. van Oosterom Belgium 32 9.3k 0.9× 10.1k 1.2× 2.8k 0.7× 4.5k 1.2× 2.4k 0.7× 89 21.9k
Michaele C. Christian United States 28 9.4k 0.9× 6.9k 0.8× 2.7k 0.7× 3.6k 1.0× 2.5k 0.8× 48 18.5k
Jan Bogaerts Belgium 39 16.2k 1.5× 12.0k 1.4× 7.1k 1.9× 4.5k 1.2× 5.2k 1.6× 114 30.1k
Pierfranco Conté Italy 73 16.9k 1.6× 7.7k 0.9× 6.4k 1.7× 5.7k 1.6× 2.8k 0.9× 699 26.1k

Countries citing papers authored by Patrick Therasse

Since Specialization
Citations

This map shows the geographic impact of Patrick Therasse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Therasse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Therasse more than expected).

Fields of papers citing papers by Patrick Therasse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Therasse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Therasse. The network helps show where Patrick Therasse may publish in the future.

Co-authorship network of co-authors of Patrick Therasse

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Therasse. A scholar is included among the top collaborators of Patrick Therasse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Therasse. Patrick Therasse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dizier, Benjamin, Andrea Callegaro, Muriel Debois, et al.. (2019). A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(7). 1725–1735. 13 indexed citations
2.
Seymour, Lesley, Jan Bogaerts, Andrea Perrone, et al.. (2017). iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 18(3). e143–e152. 1528 indexed citations breakdown →
3.
Schwartz, Lawrence H., Saskia Litière, Elisabeth G.E. de Vries, et al.. (2016). RECIST 1.1—Update and clarification: From the RECIST committee. European Journal of Cancer. 62. 132–137. 1206 indexed citations breakdown →
4.
Hoang‐Xuan, Khê, Andreas F. Hottinger, Agustí Alentorn, et al.. (2016). Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology. 34(15_suppl). 2033–2033. 5 indexed citations
5.
Schwartz, Lawrence H., Lesley Seymour, Saskia Litière, et al.. (2016). RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European Journal of Cancer. 62. 138–145. 221 indexed citations
6.
Therasse, Patrick & Jean‐Pierre Abastado. (2016). Servier’s Pipeline in Oncology: Moving from Research to Patients. Future Oncology. 12(5). 589–594. 2 indexed citations
7.
Badzio, A., Marzena Wełnicka-Jaśkiewicz, Jan Bogaerts, et al.. (2010). Pattern of care in locally advanced breast cancer: Focus on local therapy. The Breast. 20(2). 145–150. 17 indexed citations
8.
Trimble, Edward L., Jeffrey S. Abrams, Ralph M. Meyer, et al.. (2009). Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology. 27(30). 5109–5114. 35 indexed citations
9.
Burzykowski, Tomasz, Marc Buyse, Martine Piccart, et al.. (2008). Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1987–1992. 268 indexed citations
10.
11.
Piccart, Martine, Tomasz Burzykowski, Marc Buyse, et al.. (2008). Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1980–1986. 164 indexed citations
12.
Verweij, Jaap, Patrick Therasse, & Elizabeth A. Eisenhauer. (2008). Cancer clinical trial outcomes: Any progress in tumour-size assessment?. European Journal of Cancer. 45(2). 225–227. 22 indexed citations
13.
Buyse, Marc, Sherene Loi, Laura van’t Veer, et al.. (2006). Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. JNCI Journal of the National Cancer Institute. 98(17). 1183–1192. 842 indexed citations breakdown →
14.
Bogaerts, Jan, Fátima Cardoso, Marc Buyse, et al.. (2006). Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nature Clinical Practice Oncology. 3(10). 540–551. 172 indexed citations
15.
Legrand, Catherine, Luc Duchateau, Richard Sylvester, et al.. (2006). Heterogeneity in disease free survival between centers: lessons learned from an EORTC breast cancer trial. Clinical Trials. 3(1). 10–18. 11 indexed citations
16.
Therasse, Patrick, Susan G. Arbuck, Elizabeth A. Eisenhauer, et al.. (2005). New guidelines to evaluate the response to treatment in solid tumors. Breast Cancer. 12(S1). S16–S27. 476 indexed citations
17.
Tombal, Bertrand, et al.. (2005). Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. The Prostate. 65(2). 178–187. 66 indexed citations
18.
Bottomley, Andrew & Patrick Therasse. (2002). Quality of life in patients undergoing systemic therapy for advanced breast cancer. The Lancet Oncology. 3(10). 620–628. 65 indexed citations
19.
Therasse, Patrick, et al.. (2001). The Importance of Quality Assurance in Surgical Oncology in the Treatment of Colorectal Cancer. Surgical Oncology Clinics of North America. 10(4). 885–914. 12 indexed citations
20.
Therasse, Patrick, Susan G. Arbuck, Elizabeth A. Eisenhauer, et al.. (2000). New Guidelines to Evaluate the Response to Treatment in Solid Tumors. JNCI Journal of the National Cancer Institute. 92(3). 205–216. 13583 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaret Mooney Breakdown of academic impact, for papers by Stephen J. Gwyther Breakdown of academic impact, for papers by P. Therasse Breakdown of academic impact, for papers by E. Eisenhauer Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Lalitha Shankar Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Michaele C. Christian Breakdown of academic impact, for papers by Jan Bogaerts Breakdown of academic impact, for papers by Pierfranco Conté
Rankless by CCL
2026